問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of Others--

Division of General Internal Medicine

Division of General Internal Medicine

Taichung Veterans General Hospital

Division of Cardiovascular Diseases

National Taiwan University Hospital Hsin-Chu Branch

Division of Hematology & Oncology

CHANGHUA CHRISTIAN HOSPITAL

Division of Hematology & Oncology

更新時間：2023-09-19

吳尚儒Wu, Shang-Ju
  • Principal Investigator
  • Clinical Trial Experience (year) -18 years -4 個月

Recruiting Trial

74Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳尚儒

List

135Cases

2023-07-01 - 2027-05-30

Phase I/II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Not yet recruiting2Sites

2023-07-31 - 2029-02-28

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Recruiting12Sites

2023-09-01 - 2028-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2023-10-15 - 2033-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

2023-10-20 - 2028-09-22

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2023-12-01 - 2027-07-01

Phase I/II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2026-09-01 - 2029-06-30

Phase II

Not yet recruiting
A phase 2, randomized, double-blind, placebo-controlled trial was conducted to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFrEF).

  • Condition/Disease

    Heart failure with reduced ejection fraction

  • Test Drug

    CRD-4730

Participate Sites
4Sites

Not yet recruiting4Sites

2024-02-01 - 2038-01-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2024-03-01 - 2027-12-31

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
1Sites

Recruiting1Sites

2024-07-30 - 2028-09-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Not yet recruiting8Sites

Recruiting4Sites

1 2 3 4 5 14
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB